Phase 2 randomized trial: immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults
21 Jul, 2020 | 09:29h | UTCCommentaries: China’s Ad5 vectored COVID-19 vaccine safe and induces immune response – News Medical AND CanSino COVID-19 vaccine generates immune response in 90% of patients – UPI
Related Commentary on Twitter
NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT pic.twitter.com/olXJsOgTFv
— The Lancet (@TheLancet) July 20, 2020